Boston Scientific Q3 Sales Rise 1.5% to $5.14 Billion as It Guides to a Fourth-Quarter Decline

Boston Scientific said third-quarter sales grew just 1.5% in a year its CEO called challenging after a cybersecurity incident, and the medical device maker now expects fourth-quarter sales to decline from a year earlier.

The Marlborough, Massachusetts, company reported net sales of $5.138 billion for the quarter ended Sept. 30, compared with $5.065 billion a year ago, according to the earnings release it filed with an 8-K on Wednesday. Growth was 1.5% on a reported, operational and organic basis.

Profit slips

Net income attributable to common stockholders fell to $582 million, or 40 cents a share, from $755 million, or 51 cents, a year earlier. Adjusted earnings, which exclude amortization, restructuring, litigation and other items, were 73 cents a share versus 75 cents.

The quarter carried $81 million of litigation-related net charges, $63 million of restructuring net charges and $39 million of intangible asset impairment charges, according to the company's income statement. Gross profit dipped to $3.428 billion from $3.542 billion as cost of products sold rose.

"This has been a challenging year for Boston Scientific and I'm proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients," Chairman and CEO Mike Mahoney said. The company's forward-looking statements refer to a cybersecurity incident first reported on Aug. 26, 2026.

Where sales came from

• Cardiovascular: $3.406 billion, up 1.9%
• MedSurg: $1.733 billion, up 0.6% reported
• Neuromodulation: $331 million, up 13.1%
• Urology: $661 million, down 3.2%
• Endoscopy: $741 million, down 0.8%

U.S. sales rose 0.5% to $3.309 billion. Europe, the Middle East and Africa grew 4.4% on a reported basis and 6.1% operationally, while Latin America and Canada jumped 16.0%. Asia-Pacific slipped 0.6%.

The company also highlighted pipeline steps, including starting enrollment in a clinical trial for its next-generation WATCHMAN Elite left atrial appendage closure device and FDA 510(k) clearances for two kidney stone technologies and an expanded size range of its SEISMIQ peripheral lithotripsy catheter. It also announced a collaboration with Heartflow on AI-powered, CT-guided planning for coronary procedures.

Outlook points lower for the fourth quarter

Boston Scientific now estimates full-year 2026 net sales growth of about 4.25% on a reported basis and about 3.75% organically, with adjusted earnings of $3.16 to $3.18 a share.

For the fourth quarter, the company expects net sales to decline about 1.0% to 3.0% from a year earlier on a reported and organic basis, with adjusted earnings of 77 to 79 cents a share.

What comes next

Management scheduled a conference call for 8 a.m. ET on Wednesday to discuss the results. Through nine months, net sales totaled $15.784 billion, up from $14.788 billion a year earlier, and net income attributable to common stockholders reached $2.830 billion, according to the release.

Sources

1. Boston Scientific Form 8-K with third-quarter 2026 earnings release (Exhibit 99.1), filed Oct. 28, 2026 (accession 0000885725-26-000066)

This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.

Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.